Biological
zamtocabtagene autoleucel (MB-CART2019.1)
zamtocabtagene autoleucel (MB-CART2019.1) is a biological therapy with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph phase_2
3
100%
Phase Distribution
0
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Recruiting2
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 23 (100.0%)
Trials by Status
recruiting267%
not_yet_recruiting133%
Recent Activity
2 active trials
Showing 3 of 3
not_yet_recruitingphase_2
Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL
NCT07569965
recruitingphase_2
Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms
NCT06508931
recruitingphase_2
DALY II USA/ MB-CART2019.1 for DLBCL
NCT04792489
Clinical Trials (3)
Showing 3 of 3 trials
NCT07569965Phase 2
Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL
NCT06508931Phase 2
Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms
NCT04792489Phase 2
DALY II USA/ MB-CART2019.1 for DLBCL
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3